The accelerated approval from the U.S. Meals and Drug Administration (FDA) of Modeyso (dordaviprone) for sufferers with diffuse midline glioma with an H3 K27M mutation, is a step in the suitable course however extra work stays, as an skilled defined in an interview with CURE.
“It is positively an vital step ahead in a discipline the place nothing has been authorised, however it advantages solely a subset of sufferers, and so we nonetheless want loads of work to enhance on the outcomes,” mentioned Dr. Patrick Wen, Director of the Middle for Neuro-Oncology at Dana-Farber Most cancers Institute and Professor of Neurology at Harvard Medical Faculty in Boston.
Wen was the senior creator of a research revealed within the Journal of Scientific Oncology that discovered monotherapy with Modeyso to be well-tolerated, with sturdy and clinically significant effectiveness amongst sufferers with recurrent H3 K27M-mutant diffuse midline glioma.
The accelerated approval is for Modeyso for the remedy of grownup and pediatric sufferers aged one yr and older with diffuse midline glioma harboring an H3 K27M mutation and progressive illness following prior remedy. It’s, based on the company, the primary FDA-approved systemic remedy for H3 K27M-mutant diffuse midline glioma.
Transcript
For sufferers with glioma, what must be the large takeaway from this FDA approval?
Of all of the kinds of gliomas, that is most likely the toughest one to deal with, as a result of being within the midline, it is not resectable by surgical procedure, they usually normally do not reply to the usual chemotherapies, so all these sufferers have is simply radiation, which works for quite a lot of months, after which the tumor recurs. And so most sufferers have a life expectancy of a few yr or so. So it is a horrible illness that happens in younger adults and infrequently in in kids. Till this approval, there was no remedy other than radiation for these sufferers.
This approval is predicated on a research that’s not for all diffuse midline glioma sufferers with an H3 K27M mutation. It was completed in a research primarily for the sufferers who had thalamic gliomas, and primarily in adults, and that was as a result of it is very laborious to inform if a drug is working in these tumors. The extra frequent diffuse, intrinsic pontine glioma, as an example, should not enhancing so it is very laborious to measure the tumor. And so the FDA wished a set of sufferers that they may assess response charge. And in order that’s why this research checked out 50 sufferers with measurable tumor, they weren’t a DIPG sufferers or spinal twine sufferers, and so it was primarily based on the response charge and the sturdiness of the response that led to the approval.
So it is positively an vital step ahead in a discipline the place nothing has been authorised, however it advantages solely a subset of sufferers, and so we nonetheless want loads of work to enhance on the outcomes. However now that this drug is offered, probably, you might consider mixture therapies and different novel methods to attempt to construct on this step. The drug may be very effectively tolerated — most focused therapies should not that straightforward for sufferers to take, this one is definitely very straightforward. You are taking it as soon as every week, and there will be some fatigue, nausea, complications, however more often than not, sufferers do not feel dangerous on it in any respect, and loads of them will not have uncomfortable side effects that they’re going to let you know about. So hopefully it will permit the drug to be pretty simply mixed with different medication, and that may construct on these preliminary steps.
References
- “FDA grants accelerated approval to dordaviprone for diffuse midline glioma,” by the U.S. FDA. Information launch. Aug. 6., 2025. https://www.fda.gov/medication/resources-information-approved-drugs/fda-grants-accelerated-approval-dordaviprone-diffuse-midline-glioma
- “ONC201 (Dordaviprone) in Recurrent H3 K27M-Mutant Diffuse Midline Glioma,” by Dr. Isabel Arrillaga-Romany. The Journal of Scientific Oncology. Might 1, 2024.
For extra information on most cancers updates, analysis and training, don’t overlook to subscribe to CURE®’s newsletters right here.
